Article Text

Download PDFPDF
▼Dapagliflozin (Forxiga) for type 2 diabetes?

Abstract

In the UK, diabetes mellitus affects around 3 million people, of whom over 90% have type 2 diabetes.1 Aims of treatment include minimising long-term complications (e.g. cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding unwanted effects of treatment (e.g. severe hypoglycaemia, weight gain).2 Management of diabetes includes patient support and education; addressing symptoms; lifestyle modification; targeting associated risk factors for cardiovascular disease; and surveillance for, and management of, complications including treatment-related hypoglycaemia.2 ▼Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.3 It is licensed in the UK in adults with type 2 diabetes as monotherapy when diet and exercise alone do not provide adequate glycaemic control and who are unable to tolerate metformin; or, as add-on therapy, with other glucose-lowering agents including insulin, when these, with diet and exercise, do not provide adequate glycaemic control.3 The company's advertising materials claim that dapagliflozin provides a “novel method of controlling excess glucose” with “secondary benefit of weight loss”. Here, we review the evidence for the use of dapagliflozin in the management of type 2 diabetes mellitus.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.